Arcturus Therapeutics (ARCT) PT Lowered to $93 at Brookline Capital Markets, Following Clinical Business Update
Tweet Send to a Friend
Brookline Capital Markets analyst Kumaraguru Raja lowered the price target on Arcturus Therapeutics (NASDAQ: ARCT) to $93.00 (from $101.00) while ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
